
    
      A pilot phase was conducted in 3 male subjects before the main phase for assessment of
      absolute bio-availability conducted in 16 other male subjects. The pilot phase aimed to
      determine the intravenous dose to be used in the main phase based on safety data and
      pharmacokinetics data.
    
  